ES2159552T3 - Terapia de sustitucion de hormonas. - Google Patents

Terapia de sustitucion de hormonas.

Info

Publication number
ES2159552T3
ES2159552T3 ES94909721T ES94909721T ES2159552T3 ES 2159552 T3 ES2159552 T3 ES 2159552T3 ES 94909721 T ES94909721 T ES 94909721T ES 94909721 T ES94909721 T ES 94909721T ES 2159552 T3 ES2159552 T3 ES 2159552T3
Authority
ES
Spain
Prior art keywords
substitution therapy
hormone substitution
hormone
estrogen
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94909721T
Other languages
English (en)
Inventor
Gary D Hodgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
Original Assignee
Eastern Virginia Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2159552(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eastern Virginia Medical School filed Critical Eastern Virginia Medical School
Application granted granted Critical
Publication of ES2159552T3 publication Critical patent/ES2159552T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)
  • Prostheses (AREA)

Abstract

UN METODO DE TERAPIA DE SUSTITUCION DE HORMONA INCLUYE LA ADMINISTRACION DE ESTROGENO JUNTO CON UNA CANTIDAD DE ANTIPROGESTINA QUE INHIBE LA PROLIFERACION ENDOMETRIAL INDUCIDA POR ESTROGENO EN UNA MUJER.
ES94909721T 1993-02-25 1994-02-18 Terapia de sustitucion de hormonas. Expired - Lifetime ES2159552T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/023,692 US5468736A (en) 1993-02-25 1993-02-25 Hormone replacement therapy

Publications (1)

Publication Number Publication Date
ES2159552T3 true ES2159552T3 (es) 2001-10-16

Family

ID=21816657

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94909721T Expired - Lifetime ES2159552T3 (es) 1993-02-25 1994-02-18 Terapia de sustitucion de hormonas.

Country Status (25)

Country Link
US (1) US5468736A (es)
EP (1) EP0686037B1 (es)
JP (1) JP3441459B2 (es)
KR (1) KR100248857B1 (es)
AT (1) ATE202281T1 (es)
AU (1) AU680239B2 (es)
BG (1) BG62383B1 (es)
BR (1) BR9406667A (es)
CA (1) CA2157003C (es)
CZ (1) CZ290562B6 (es)
DE (1) DE69427529T2 (es)
DK (1) DK0686037T3 (es)
ES (1) ES2159552T3 (es)
FI (1) FI953926L (es)
GR (1) GR3036649T3 (es)
HU (1) HU221169B1 (es)
NO (1) NO309456B1 (es)
NZ (1) NZ262657A (es)
PL (1) PL176796B1 (es)
PT (1) PT686037E (es)
RO (1) RO115115B1 (es)
RU (1) RU2139056C1 (es)
SK (1) SK282921B6 (es)
UA (1) UA43842C2 (es)
WO (1) WO1994018983A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
AU5942700A (en) * 1996-03-11 2000-11-30 Schering Aktiengesellschaft Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US20060014728A1 (en) * 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
EE200200102A (et) * 1999-08-31 2003-04-15 Jenapharm Gmbh & Co. Kg Mesoprogestiinid (progesterooniretseptori modulaatorid) hormoonasendusravi (HAR) kompositsioonide komponendina
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
US6432643B1 (en) 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
BR0108107A (pt) * 2000-01-28 2003-03-11 Endorech Inc Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
PT1390040E (pt) * 2001-05-18 2007-04-30 Pantarhei Bioscience Bv Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
ES2337129T3 (es) * 2001-05-23 2010-04-21 Pantarhei Bioscience B.V. Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US8026228B2 (en) * 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DE10200405A1 (de) 2002-01-08 2002-08-01 Zimmer Ag Spinnvorrichtung und -verfahren mit Kühlbeblasung
DE10204381A1 (de) 2002-01-28 2003-08-07 Zimmer Ag Ergonomische Spinnanlage
DE10206089A1 (de) 2002-02-13 2002-08-14 Zimmer Ag Bersteinsatz
CN100352445C (zh) * 2002-06-11 2007-12-05 潘塔希生物科学股份有限公司 一种皮肤护理组合物及其用途
PT1511496E (pt) * 2002-06-11 2007-01-31 Pantarhei Bioscience Bv Método para tratamento ou prevenção de doenças mediadas pelo sistema imunitário e formulação farmacológica para utilização nas mesmas
SI1526856T1 (sl) * 2002-07-12 2008-04-30 Pantarhei Bioscience Bv Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
SI1556058T1 (sl) * 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
SI1624878T1 (sl) * 2003-05-22 2007-02-28 Pantarhei Bioscience Bv Uporaba sestavkov, ki obsegajo estrogensko komponento, za zdravljenje in preprecevanje muskuloskeletne bolecine
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
AU2007327707B2 (en) 2006-10-24 2012-07-12 Allergan pharmaceuticals International Ltd. Compositions and methods for suppressing endometrial proliferation
ATE473746T1 (de) * 2007-01-08 2010-07-15 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
WO2016090139A1 (en) * 2014-12-03 2016-06-09 Evestra, Inc. Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
WO1994018983A1 (en) 1994-09-01
CZ204895A3 (en) 1996-03-13
PL176796B1 (pl) 1999-07-30
NZ262657A (en) 1997-05-26
JPH08510993A (ja) 1996-11-19
HUT72080A (en) 1996-03-28
SK282921B6 (sk) 2003-01-09
EP0686037B1 (en) 2001-06-20
AU680239B2 (en) 1997-07-24
GR3036649T3 (en) 2001-12-31
KR100248857B1 (ko) 2000-04-01
FI953926A0 (fi) 1995-08-22
NO953243D0 (no) 1995-08-17
PT686037E (pt) 2001-09-28
SK104995A3 (en) 1997-04-09
RU2139056C1 (ru) 1999-10-10
FI953926A7 (fi) 1995-08-22
EP0686037A1 (en) 1995-12-13
ATE202281T1 (de) 2001-07-15
RO115115B1 (ro) 1999-11-30
US5468736A (en) 1995-11-21
CA2157003C (en) 2001-04-17
DE69427529D1 (de) 2001-07-26
DE69427529T2 (de) 2001-11-22
CA2157003A1 (en) 1994-09-01
KR960700727A (ko) 1996-02-24
CZ290562B6 (cs) 2002-08-14
NO309456B1 (no) 2001-02-05
DK0686037T3 (da) 2001-08-27
HU9502306D0 (en) 1995-09-28
EP0686037A4 (en) 1997-11-26
BR9406667A (pt) 1996-01-23
NO953243L (no) 1995-08-17
AU6245494A (en) 1994-09-14
FI953926L (fi) 1995-08-22
BG99880A (bg) 1996-02-28
PL310660A1 (en) 1995-12-27
HU221169B1 (en) 2002-08-28
UA43842C2 (uk) 2002-01-15
BG62383B1 (bg) 1999-10-29
JP3441459B2 (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
ES2159552T3 (es) Terapia de sustitucion de hormonas.
FI950774A0 (fi) Valmiste käytettäväksi 3-ketodesogestreeliä sisältävään transdermaaliseen applikaatioon
MY113079A (en) Estrogen agonists as remedies for cardiovascular diseases
TW323953B (en) A pharmaceutical composition used to prevent or treat non-inflammatory-induced high intraocular pressure related to the application of steroids or endogenous steroids
ATE304845T1 (de) Hautpflaster enthaltend testosteron und gegebenenfalls estrogen
ATE155694T1 (de) Verzweigung
NO931209L (no) Anordning for tarnsdermal tilfoersel av kontraseptiver
MY118392A (en) Variable day start tablet dispenser
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
GB2318055A (en) Dosage form comprising oxybutynin
BR9612207A (pt) Processo e kit para contracepções em mamíferos fêmeas consistindo de uma combinação de gestageno e estrogênio
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
ES2184866T3 (es) Composicion de tampon para reactivos de dosificado inmunologico.
IL141914A0 (en) Dosage form comprising liquid formulation
MX9703144A (es) Envase de seguridad frente a la accion de los niños para colocar parches portadores de principios activos.
EA199700449A1 (ru) Способ предотвращения остеопороза
DE69015785D1 (de) Neutralisierbares Reduzierventil.
YU48719B (sh) Lizin so 6-hloro-5-fluoro-3-(2-tenoil)-2-oksindol-1-karboksamida
MX9707009A (es) Inyeccion de una vez al mes como un contraceptivo de base y para terapia de reemplazamiento hormonal para mujeres perimenopausicas y premenopausicas.
ECSP941115A (es) Composicion de fibra dietetica. metodo de preparacion y uso
MX9709426A (es) Uso de alendronato para preparar composiciones para la prevencion de la osteoporosis.
ES2141044B1 (es) Terapia con oxibutinina.
SK689U (sk) Obálka s doručenkou
UA10683A (uk) Засіб для лікувальhих ваhh
ES257833U (es) Panel luminoso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 686037

Country of ref document: ES